PERIGON PHARMACY THREE SIXTY
Live / Registered — Registered (as of 21 Jul 2026)
What this means for you
Registered since 21 Jul 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 21 Jul 2032: the §8 declaration of use).
Record
- Serial number
- 98445795
- Registration number
- 8356664
- Mark type
- Slogan / phrase
- Filed
- 12 Mar 2024
- Published for opposition
- 01 Apr 2025
- Registered
- 21 Jul 2026
- Next maintenance filing
- §8 declaration of use, due by 21 Jul 2032 (grace period to 21 Jan 2033)
- Attorney of record
- James M. Theo
Goods and services
- Class 005 — Pharmaceuticals: Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of rare and chronic health conditions.
Owner
- Tespo Health Holdings LLC, Plymouth, MI, US
- Tespo Health Holdings LLC, Plymouth, MI, US
- Tespo Health Holdings LLC, Plymouth, MI, US
Prior registrations
Board proceedings on this mark
- Extension of Time to Oppose No. 98445795 — Perrigo Pharma International v. Tespo Health Holdings LLC, filed 29 Apr 2025 (Terminated)
Prosecution history
- 21 Jul 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 21 Jul 2026 — REGISTERED-PRINCIPAL REGISTER
- 01 Jul 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 01 Jul 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 02 Jun 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 11 Feb 2026 — USE AMENDMENT FILED
- 11 Feb 2026 — TEAS STATEMENT OF USE RECEIVED
- 16 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 10 Aug 2025 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 29 Apr 2025 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 01 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Apr 2025 — PUBLISHED FOR OPPOSITION
- 26 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 07 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED